CTL Fiscal Year 2024 Facts & Figures

 CTL works diligently with Cornell researchers and innovators by bringing their inventions from the lab to the marketplace. As Cornell’s technology commercialization office, we are exploring new ways to create business opportunities, launching new ventures, and helping to commercialize Cornell technologies. Learn more about CTL’s annual activities and metrics.

Commercializing

109
Licenses & Options

FY2020-2024:
477 Licenses & Options

$22 M
Revenue Generated

FY2020-2024:
$122M Revenue Generated

Venturing

10
New Startups Based on Cornell IP
$418.6 M
Funding Raised by Startups in FY24

Cornell Tech Runway:

  • Neuralenz
  • Kubbly
  • BiaWear

Cornell-licensed Startups:

  • Anova Biomedical
  • Astoria Biologica
  • Carbon to Stone
  • ExoPower
  • Giant Biosystems
  • Graphenode
  • Sacyl Pharmaceuticals

FY2020-2024:
$2.3B Funding Raised by Startups

Accelerating

23
Ignite Gap Funding Projects
Ignite Impact
$180.9 M
Follow-on Funding

Protecting

169
US Non-Provisional Patent Applications
Filed Location 2020 2021 2022 2023 2024
U.S. Provisional 158 163 163 164 143
U.S. Nonprovisional 195 179 164 169 169
International 322 304 318 217 251
Total 675 646 645 550 544
107
US Issued Patents
FY 2020 2021 2022 2023 2024
U.S. 124 127 79 104 107
International 284 191 142 117 144
Total 408 318 221 221 251

Ideating

Panelists during the "Building Bridges from Scientific Discovery to Societal Impact"
34
Educational Programs Offered
Two people talking in front of posters
70
Office Hours
Minglin Ma encapsulation device for type 1 diabetes
313
IP Disclosures

Recent News

Syringe with vials of liquid

Cornell Researchers Launch Vaccine Startup After Ignite Programs

| COVID-19 Technology, News, News Ignite | No Comments
Cornell researchers recently published a study on a proprietary new vaccine platform that could provide better protection from COVID-19 and different strains of influenza. In the study, mouse models showed…
The 2024 Fuzehub Commercialization Competition Winners gather together for a group photo.

Anova Biomedical Secures Top Prize at FuzeHub Competition

| Commercialization, News | No Comments
The grand prize winner of the Fuzehub 2024 Commercialization Competition, held during the New York State Innovation Summit, was Anova Biomedical Inc., a current Center for Life Science Ventures member…
Anova Biomedical's first-of-its-kind biodegradable graft material for cardiovascular patients not only expands and contracts likek blood vessels; it is also absorbed into the body as new cells take its place.

Ignite Alum Joins Center for Life Science Ventures

| News, News Ignite | No Comments
Anova Biomedical, a Cornell spinout developing biodegradable vascular grafts, recently joined the university’s Center for Life Science Ventures.   Co-founders Anthony D’Amato, a former postdoctoral researcher, and Yadong Wang, the McAdam…
Héctor D. Abruña

Cornell Inventor Héctor D. Abruña Wins Prestigious Fermi Award

| Commercialization, News | No Comments
Héctor D. Abruña, the Émile M. Chamot Professor of Chemistry in the Department of Chemistry and Chemical Biology in Cornell’s College of Arts and Sciences, recently won the Enrico Fermi…